drugset / Trial / NCT07263425

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis

NCT07263425

NaSingle-groupOpen-labelTreatment

Summary

Evaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis

Timeline

Start
2025-10-27
Primary completion
2027-10-27
Completion
2027-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Thiotepa Other / unclassified 10 mg Intrathecal
Subject Trastuzumab Monoclonal antibody 150 mg Intrathecal

Indications